Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
01:03pm, Friday, 17'th Jan 2025
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)
09:38pm, Monday, 13'th Jan 2025
Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Confer
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 01'st Jan 2025
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks.
07:55am, Wednesday, 01'st Jan 2025
Investing in dividend stocks can be an excellent way to boost your income each year. But the challenge can be generating a good return while keeping your risk low.
Organon (OGN) Ascends While Market Falls: Some Facts to Note
06:56pm, Friday, 27'th Dec 2024
Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:00am, Friday, 20'th Dec 2024
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
07:30am, Thursday, 19'th Dec 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th.
Organon price target raised to $20 from $19 at Goldman Sachs
05:42pm, Tuesday, 17'th Dec 2024
Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment
Final Trades: Amazon, American Express and Organon
01:40pm, Tuesday, 10'th Dec 2024
The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 09'th Dec 2024
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
10:00am, Tuesday, 26'th Nov 2024
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 15'th Nov 2024
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon: 7% Yield, 4x P/E, Big Upside Potential
12:42pm, Thursday, 14'th Nov 2024
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has show
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
08:30am, Wednesday, 13'th Nov 2024
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue g
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
10:00am, Monday, 04'th Nov 2024
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
